U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07789431) titled 'OM336 in Sensitized Transplant Candidates' on Aug. 14.
Brief Summary: This investigator-initiated, single-arm, open-label Phase IIa pilot study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OM336 in highly HLA-sensitized adults with chronic kidney disease awaiting kidney transplantation. The study will enroll 12 participants who have either a very low likelihood of receiving a compatible deceased donor kidney because of broad HLA sensitization or unacceptable donor-specific antibodies against a potential living donor.
Participants will receive one 4-week course of subcutaneo...